MWNA
GYRE icon

Marshall Wace North America’s Gyre Therapeutics GYRE Stock Holding History

Marshall Wace North America’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,889
Closed -$96K – 1380
2019
Q4 		$96K Buy
+1,889
New +$79.2K ﹤0.01% 1067
2019
Q2 		– Sell
-217
Closed -$13K – 1323
2019
Q1 		$13K Buy
217
+55
+34% +$3.53K ﹤0.01% 1435
2018
Q4 		$10K Buy
+162
New +$11.9K ﹤0.01% 1420

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Marshall Wace North America's GYRE Position: Q1 2020 in Review

Marshall Wace North America sold out of Gyre Therapeutics (GYRE) in Q1 2020, closing a stake of 1,889 shares — an estimated $96K sold.

Marshall Wace North America first reported a position in GYRE in Q4 2018 and held it in 3 quarters. The position peaked at $96K in Q4 2019. 46 funds tracked by Wall St. Rank hold GYRE as of Q1 2020.

  • Marshall Wace North America reported no remaining Gyre Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Marshall Wace North America sold 1,889 Gyre Therapeutics shares in Q1 2020, an estimated $96K.
  • Marshall Wace North America first reported a position in Gyre Therapeutics in Q4 2018 and held it in 3 quarters.
  • Marshall Wace North America's Gyre Therapeutics position peaked at $96K in Q4 2019.
  • 46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2020.

Based on Marshall Wace North America's 13F filing for Q1 2020, filed 15 May 2020.